Q3 EPS Estimate for Quest Diagnostics Decreased by Analyst

Key Points

• Quest Diagnostics' Q3 2025 EPS estimate has been lowered by Leerink Partners to $2.52, down from $2.53, with a full-year estimate of $9.70 per share.
• The company recently posted Q2 earnings of $2.62 EPS, exceeding analyst expectations and reporting a revenue of $2.76 billion, which is a 15.2% increase year-over-year.
• Quest Diagnostics declared a quarterly dividend of $0.80, scheduled for payment on October 20th, representing an annualized yield of 1.8%.

Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of Quest Diagnostics in a research note issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings per share of $2.52 for the quarter, down from their previous forecast of $2.53. The consensus estimate for Quest Diagnostics' current full-year earnings is $9.70 per share. Leerink Partnrs also issued estimates for Quest Diagnostics' Q4 2025 earnings at $2.45 EPS, FY2027 earnings at $11.74 EPS and FY2028 earnings at $12.86 EPS.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, topping analysts' consensus estimates of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The business had revenue of $2.76 billion during the quarter, compared to analysts' expectations of $2.73 billion. During the same quarter last year, the company posted $2.35 earnings per share. Quest Diagnostics's quarterly revenue was up 15.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS.

Other equities analysts have also recently issued research reports about the company. UBS Group reduced their price target on Quest Diagnostics from $176.00 to $175.00 and set a "neutral" rating for the company in a report on Friday, July 18th. Evercore ISI lifted their price target on Quest Diagnostics from $185.00 to $190.00 and gave the stock an "in-line" rating in a report on Wednesday. Baird R W cut Quest Diagnostics from a "strong-buy" rating to a "hold" rating in a report on Monday, August 25th. William Blair reiterated an "outperform" rating on shares of Quest Diagnostics in a report on Wednesday, July 23rd. Finally, Wall Street Zen downgraded shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $186.63.

Quest Diagnostics Trading Down 0.6%

Quest Diagnostics stock opened at $180.85 on Thursday. Quest Diagnostics has a 52 week low of $146.91 and a 52 week high of $191.49. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.99 and a current ratio of 1.09. The stock has a market capitalization of $20.22 billion, a P/E ratio of 21.66, a PEG ratio of 2.41 and a beta of 0.56. The stock has a 50-day simple moving average of $180.66 and a 200 day simple moving average of $175.26.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 20th. Stockholders of record on Friday, October 3rd will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, October 3rd. Quest Diagnostics's payout ratio is presently 38.32%.

Insider Activity

In other news, SVP Patrick Plewman sold 1,975 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $185.00, for a total value of $365,375.00. Following the completion of the sale, the senior vice president directly owned 15,269 shares in the company, valued at approximately $2,824,765. The trade was a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael E. Prevoznik sold 227 shares of Quest Diagnostics stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president owned 38,117 shares of the company's stock, valued at approximately $7,170,951.21. The trade was a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,186 shares of company stock worth $9,647,471. Corporate insiders own 8.16% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. increased its stake in Quest Diagnostics by 126.9% in the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company's stock valued at $27,000 after acquiring an additional 85 shares during the last quarter. MTM Investment Management LLC bought a new position in Quest Diagnostics in the second quarter valued at approximately $29,000. AlphaQuest LLC increased its stake in Quest Diagnostics by 18,400.0% in the second quarter. AlphaQuest LLC now owns 185 shares of the medical research company's stock valued at $33,000 after acquiring an additional 184 shares during the last quarter. First Horizon Advisors Inc. increased its stake in Quest Diagnostics by 76.6% in the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company's stock valued at $32,000 after acquiring an additional 82 shares during the last quarter. Finally, Golden State Wealth Management LLC increased its stake in Quest Diagnostics by 157.3% in the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock valued at $33,000 after acquiring an additional 118 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.